Indiana University, Paradigm Conducting Trial Using NGS to Direct Therapy for TNBC Patients | GenomeWeb

The last paragraph of this article has been corrected to note that the $150 million in funding is in support of the Strategic Research Initiative.

NEW YORK (GenomeWeb) – Researchers at Indiana University have announced the launch of a new study in which they will use targeted sequencing provided by testing firm Paradigm to try to direct personalized treatment strategies for women with triple-negative breast cancer (TNBC) in the hopes of extending their lives.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.